pentavalent antimonials are still the first drug of choice for the treatment of cutaneous leishmaniasis (cl). like other treatments, they can cause adverse reactions including musculoskeletal pain , gastrointestinal disturbances, and mild to moderate headaches. in this paper, we report the first case of an infant who developed acute urticaria after her mother’s parenteral use of meglumine antim...

The leishmanicidal activity of four batches of meglumine antimoniate, produced in Farmanguinhos-Fiocruz, Brazil (TAMs), was assessed and compared to Glucantime-Aventis Pharma Ltda. Using the amastigote-like in vitro model, the active concentrations of Sb v varied from 10microg/ml to 300microg/ml for L. (L.) chagasi and from 50microg/ml to 300microg/ml for L. (L.) amazonensis, with no statistica...

Pentavalent antimonials are still the first drug of choice for the treatment of cutaneous leishmaniasis (CL). Like other treatments, they can cause adverse reactions including musculoskeletal pain, gastrointestinal disturbances, and mild to moderate headaches. In this paper, we report the first case of an infant who developed acute urticaria after her mother's parenteral use of meglumine antimo...

Pentavalent antimonial drugs such as meglumine antimoniate (Glucantime [Glu; Sanofi-Aventis, São Paulo, Brazil]) produce severe side effects, including cardiotoxicity and hepatotoxicity, during the treatment of leishmaniasis. We evaluated the role of residual Sb(III) in the hepatotoxicity of meglumine antimoniate, as well as the protective effect of the antioxidant ascorbic acid (AA) during ant...

UNLABELLED Cutaneous leishma iasis (CL) is zoonosis with a spectrum of cutaneous manifestations caused by protozoan parasites of thegenus Leishmania.Manifestation varies according to the parasite virulence and the host immune response. Pentavalent antimonials (sodium stibogluconate and meglumine antimoniate) have been used as a first-line therapy for the last 70 years around the world.We report...

Pentavalent antimony, as meglumine antimoniate (Glucantime) or sodium stibogluconate (Pentostam), is the main treatment for leishmaniasis, a complex of diseases caused by the protozoan Leishmania, and an endemic and neglected threat in Brazil. Despite over half a century of clinical use, their mechanism of action, toxicity and pharmacokinetic data remain unknown. The analytical methods for de...

OBJECTIVES Intralesional injection of pentavalent antimoniate is recommended by the World Health Organization for the treatment of cutaneous leishmaniasis (CL). This study aimed to evaluate the adverse effects of intralesional injection of meglumine antimoniate (Glucantime(®) ) and its influence on clinical laboratory parameters. METHODS A total of 105 patients with suspected lesions and ther...

Cutaneous leishmaniasis (CL) is the most common parasitic disease transmitted by vectors in Iran. CL is endemic in many urban and rural parts of Iran and usually caused by two species of Leishmania as L. major and L. tropica transmitted to humans from parasite reservoirs by the bite of female sandflies. We report a case of ocular leishmaniasis with eyelid involvement presentation. The patient w...

BACKGROUND The present study aimed to evaluate the effect of methotrexate (MTX) alone and in combination with meglumine antimoniate (MA, Glucantime) against sensitive and MA-resistant Leishmania tropica stages in vitro. METHODS The present study was carried out in 2014 in Leishmaniasis Research Center at School of Medicine, Kerman University of Medical sciences, Kerman, Iran. The effects of M...

background: successful therapy of leishmaniasis depends on effective cellular immune response. we evaluated the effectiveness of sodium selenite and zinc sulphate as known immunomodulator materials, in combination with glucantime® in treatment of cutaneous leishmaniasis lesions resulting from leishmania ma­jor in susceptible animal model. methods: thirty three female mice weighing 18-20 g at th...